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Figure S1: Energy of LD vesicular budding mode and in vitro reconstitution, related to Figure 1 
and Movie S2 
(A) Surface tension measurement principle by using a micropipette approach. Pictures shown 
correspond to the measurement of the surface tensions of GFP-PLIN1 and mCherry-LSD1 LDs 
respectively purified from Cos7 and Drosophila cells. Scale bar is 10 µm. 
(B) Estimation of the minimal energy to provide in function of surface tension, for the budding LDs of 
different sizes. This minimal energy is considered as E = 8πκ + 4πr2γ where κ (taken here as 10 kBT) 
denotes for the membrane bending modulus and γ the surface tension. The band represents the 
range of STs of purified LDs from various cell types. For comparison, the energy provided by classical 
coat proteins for budding 50-100nm sized vesicles, such as complex protein I (COPI) and clathrin 
coats, is delineated by the horizontal line. 
(C) Illustration of the giant unilamellar vesicle (GUV) and artificial LD system. The rhodamine-PE 
fluorescence signal on the GUV relocates to the embedded artificial LDs. Scale bar is 10 µm. 
(D) Variant approach for changing the GUV phospholipid composition. GUVs made exclusively with 
phosphatidyl choline (PC) are mixed with artificial LDs that contain the phospholipid of interest and 
NBD-PE (1% w/w to phospholipids). The NDB signal relocates to the GUV membrane, suggesting that 
phospholipids on the droplet relocate also to the GUV. Scale bar is 10 µm. 
(E) The presence of oleic acid (OA) in the GUV and artificial LD made of triolein leads to the spreading 
of the droplet (the droplet is on the GUV apex). The subsequent addition in the medium of active 
bovine serum albumin captures free oleic acid molecules. The concentration of free oleic acid 
molecules on the membrane decreases and leads to the budding of the artificial LD (n=5).  
(F) The evolution of the artificial LD projected size during these manipulations is determined. Scale bar 
is 20 µm. 
 
 
Figure S2: Droplet interface bilayer formation and characterization, related to Figure 2 
(A) Formation kinetics of droplet interface bilayers having different equilibrium budding angles. The 
equilibrium angles are here reached after few seconds. Drop size is around 200 µm.  
(B) Examples of droplet interface bilayers made with other surfactants and neutral lipids. Scale bar is 
20 µm. 
(C) Replacing triolein by trioctanoate as the neutral lipid phase has no effect on the budding angle.  
(D) Quantification of the droplet interface bilayer budding angles for other surfactants in a triolein lipid 
phase. Lyso-PC* corresponds to a mixture of Lyso-PC with PA at 20/80. DPPC* corresponds to a 
mixture of DPPC with PA at 75/25. 
(E) Nomenclature of the used abbreviations. 
 
 
Figure S3: Triolein egress from different phospholipid bilayer environments, related to Figure 3  
(A-D) Additional examples of PE and PC droplet interface bilayers, as in Figure 3A, with the triolein 
signal respectively present or excluded from the bilayer (B, D). Scale bars are 50 µm. 
(E) GUVs made with PC/PE (50/50) are mixed with artificial LDs containing triolein and 5% Triolein-
pyrene (TO-pyrene). The TO-pyrene signal relocates to the GUV membrane. (F) When GUVs are 
exclusively made with PC, the TO-pyrene signal is often absent from the GUV bilayer. Scale bar is 10 
µm. 
(G) Increase of the droplet interface bilayer budding angle due to the addition of PC-in-triolein in the 
surrounding bulk phase. Rhodamine-PE reports the monolayer and bilayer membranes. Scale bar is 
30 µm. 
(H) The decrease of the Triolein-pyrene signal in the droplet interface bilayer, due to PC addition, is 
concomitant to the increase of the budding angle (Figure 3D). Scale bar is 50 µm. 
 
 
Figure S4: Measure of the surface tensions of different monolayer and droplet interface 
bilayers, related to Figure 4 
(A) Principle of the monolayer surface tension measurement by the pendant drop technique. A lipid 
drop covered by the studied lipid surfactant is formed in a buffer phase. After equilibrium is reached 
(first plateau), the monolayer is compressed until a plateau of surface tension is reached (second 
plateau), which corresponds to the full monolayer packing; for some surfactants such as 
dioleylglycerol, the first and second plateaus coincide. Examples of different lipid conditions are 
shown. The surface tension of the second plateau is defined as the monolayer surface tension γm; this 
is because drops are generated in vitro under conditions of excess surfactant to ensure maximum 
monolayer packing. Each measure was repeated three times.  
(B) Monolayer tensions for different PC/PE ratios. 
(C) The droplet interface bilayer surface tension for the different PC/PE. It is given by the 
corresponding monolayer tension (B), the budding angle (not shown), and the Young equation. 
(D) Triolein concentration in the droplet interface bilayer increases with the monolayer tension. 
(E) In silico determination of the concentration of free triolein molecules in the bilayer in function of the 
bilayer surface tension. After few nano-sec, the equilibrium concentration of free triolein in the bilayer 
in attained. Measurements presented in Figure 4E were conducted after 1.5µsec, which ensures 
equilibrium. 
(F) The budding angle is presented against the monolayer surface tension of the different lipid 
compositions tested in Figure 2. The budding transition with the monolayer tension is less clear as 
with the bilayer tension (Figure 4G). 
 
 
Figure S5: Dynamic remodeling of membrane phospholipid and tension for artificial lipid 
droplet budding, related to Figure 5 
(A) Thin layer chromatography shows that the phospholipase A2 converts DOPC from liposomes into 
Lyso-PC; the fraction of Lyso-PC generated is beneath 15%, as revealed by the band signal (B). 
Addition of adenosine triphosphate (ATP) does not enhance the action of the phospholipase.  
(C) PC/Lyso-PC GUVs are fabricated by using different phospholipid ratios. Above 20% Lyso-PC, no 
GUV is formed (1: more than 50 GUVs are observed; 0: less than 20 GUVs are observed). 
(D) Phospholipase A2 induced the budding of artificial LDs from the GUV membrane, as compared to 
the control. 
(E) Evolution of the LD projected diameter over the incubation time with or without PLA2.  
(F) Measure with the microaspiration technique of the surface tension of a GUV containing an artificial 
LD, before and after PLA2 action. The image shown is the “top” view of the image in Figure 5E. 
(G) Values of the surface tensions. These values are very likely due to the use of PA and the 
presence of triolein in the bilayer. 
(H) Another example of the side view of the budding of an artificial LD after PLA2 action. 
(I) Illustrative diagram of the topology used for developing the physical model.  
 
 
Figure S6: Characterization of cellular lipid droplet size distribution upon phospholipid and 
neutral lipid modulation, related to Figure 6 
(A) Main phenotypes of LDs, ER and neutral lipids, caused by the modulation of different proteins. 
There is systematically a concomitant modification of phospholipids or lipids, which could explain the 
alteration of LD formation. 
(B-E) Histograms of the fitting curves shown in Figure 7D, 7G, 7J, and 7N; few thousands of LD size 
were quantified for each probed condition. 
(F) The siRNA of LPCAT1 in Hela cells favors the formation of LDs slightly bigger than in WT (G, H). 
Scale bar is 10 µm. 
(I) The double inhibition of LPCAT1, by siRNA, and ATX/Lyso-PLD, by the autotaxin inhibitor, 
decreases LD size distribution in a dose-dependent manner.  
(J) The occurrence of big LDs in MAFP (Figure 6F) could be due to the accumulation of PA or 
diacylglycerols, and not to the lack of Lyso-PC. Indeed, PC is transformed to PA by the phospholipase 
D, which is blocked by 1-butanol. The treatment of cells with MAFP and 1-butanol still leads to bigger 
LDs than in WT (K, L), supporting that the MAFP phenotype is due to the lack of Lyso-PC. Scale bar is 
10 µm. 
(M) Thin layer chromatography shows, in mevalonic acid loading, the deposition of sterol esters. 
Terbinafine treatment leads to squalene deposition. 
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Triolein
MG : mono-acylglycerol (1-(7Z-tetradecenoyl)-rac-glycerol)
DG : di-acylglycerol (1-2-dioleoyl-sn-glycerol (18:1))
Pufa : 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (18:0-22:6 PC)
OA : oleic acid
Chol : cholesterol
DMPC : 1,2-dimyristoyl-sn-glycero-3-phosphocholine (14:0)
DPPC : 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (16:0)
Lyso-PC : 1-(1Z-octadecenyl)-sn-glycero-3-phosphocholine (C18)
PA : 1,2-dioleoyl-sn-glycero-3-phosphate (sodium salt) (18:1)
Phospholipid nomenclature
E
LD budding
No budding

	










DO
G-
PCPu
fa PC
Ly
so
-PC
*
OA
-PCP
I
DM
PC
*
DP
PC
* PE PA MG OACh
ol
droplet interface bilayer
dr
op
le
t i
nt
er
fa
ce
 b
ila
ye
r
Figure S3 Ben M’Barek et al. 2016
budding angle
time
br
ig
ht
fie
ld
TO
-p
yr
en
e
0 min 10 min 20 min 30 min
G
Rho-PE
A
brightfield
PE
H
PC
  



 	 




TO-pyrene
Rh
-P
E
25 min
B
D
+ TO-PC
#!
#!
time
E
fo
ca
l p
la
ne

!"F
fo
ca
l p
la
ne

Rho-PEbrightfield
dr
op
le
t
G
U
V
dr
op
le
t
TO-pyrene  #!
G
U
V
 si
gn
al
 (a
.u
.)
 si
gn
al
 (a
.u
.)
distance (μm)
distance (μm)
C
pyrene 
Rho
pyrene 
Rho
Figure S4 Ben M’Barek et al. 2016
F
A
150 160 170 180 190
0.0
0.5
1.0
1.5
time (sec)
m
on
ol
ay
er
 te
ns
io
n
 γ
m
 (m
N
/m
)
timeTriolein+PI
surface compression
γm
430 480 530
0
5
10
15
20
25
time (sec)
γm
surface compression
Triolein + PI Triolein-sterolester + PE
timeTriolein-sterol ester +PE
0 500 1000 1500
time (ns)
0
0.05
0.1
0.15
0.2
%
 T
rio
le
in
 in
 th
e 
PC
 b
ila
ye
r ST=0.0 mN/m
ST=0.7mN/m
ST=1.4 mN/m
ST=2.0 mN/m
ST=2.9 mN/m
m
on
ol
ay
er
 te
ns
io
n
 γ
m
 (m
N
/m
)
0.001 0.01 0.1 1 10 100
0
60
120
180
 (°
)






	

 	









 	
 


 
	



Trolein
Squalene
Triolein-Sterol ester
bu
dd
in
g 
an
gl
e 
monolayer tension γm (mN/m)
LD Budding
No budding
[P
C/
PE
]
B
(ST=surface tension)
bilayer tension γb (mN/m)
D
bi
la
ye
r t
rio
le
in
 c
on
ce
nt
ra
tio
n 
(a
.u
)
monolayer tension γm (mN/m)
monolayer tension γm (mN/m)
[P
C/
PE
]
C
E
    




    






 
   




Figure S5 Ben M’Barek et al. 2016
I
γb
Lyso-PC
PC
PLA2
ATP -
- - - -
- - -+ +
++
Control 
Lyso-PC
Control 
PC
A B C
0 20 40
0.0
0.5
1.0
G
U
V 
fo
rm
at
io
n
0
40
80
to
ta
l l
ip
os
om
es
 li
pi
ds
PC
Ly
so
-PC % Lyso-PC
+ PLA2
Rh
o-
PE
time
F
br
ig
ht
fie
ld
 
D E
time
br
ig
ht
fie
ld
 
Rh
o-
PE
0 15 30 45 60
0.92
0.94
0.96
0.98
1.00
1.02
time (min)
+ PLA2
- PLA2
Rh
o-
PE
br
ig
ht
fie
ld
 
+ 
PL
A
2
- P
LA
2
pr
oj
ec
te
d 
dr
op
le
t s
iz
e
(n
or
m
)
γm
γm’ θ
γb= γmcos θ + γm’
G H
brightfield Rho-PE
- P
LA
2 
+ P
LA
2
0
5
10
G
U
V 
te
ns
io
n 
(m
N
/m
) 15
Figure S6 Ben M’Barek et al. 2016

 	 
 






	 
'&#	$!
 	'&#$!
 % 	
KJ L
GF H I

% 
(
)
"



	
'&
#$!

	


 

% 



	

	


 
0.8
0.9
1
1.1
1.2
0 50 100 150
M
Squalene
Sterol ester
Terbinafine _ +
Inhibited enzyme Phenotype Affected lipid surfactants
LPCAT1,2
PLC
SCD1
Lyso PLD
AGPAT
Lipin1
Seipin
FIT2
CCT1
Lyso-PC
PLD PA, PC
___ PC, DG
PL saturation
PLs, DG
DG
PA, PL saturation
PC
PA
___ Lyso-PA, Lyso-PC
ECT1
PEMT
LPAAT
cPLA2 Distorted ER (TAG accumulation in the ER) PC, Lyso-PC
PC, PE, PSInhibition of TAG accumulation
PA, LPA
___ PC, PE
(Moessinger et al. 2014)
(Guijas et al. 2014;
 Gubern et al. 2008)
(Andersson et al. 2006;
 Nakamura et al. 2005)
(Boutet et al. 2009; 
Fei et al. 2008; 
Szymanski et al. 2007)
(Ralston & Mutch 2015;
 Shi et al. 2013)
(Krahmer et al. 2013)
(Ayciriex et al. 2012)
(Guijas et al. 2014; 
Sembongi et al. 2013; 
Adeyo et al. 2011)
___
___
___
(Gross et al. 2011; 
Kadereit et al. 2008)
(Noga et al. 2002; 
Hörl et al. 2011)
___ ___
;
(TAG accumulation
 in the ER) ;
 	 
 






 	 
 


	
	


 	 
 


	
	




 	 
 


	
	


A B C
D E
 	 
 


	
	 
 	
LD
s(
in
ih
ib
)/L
D
s(
W
T)
CATXi (μM)
LD diameter (μm)
LD diameter (μm)
LD diameter (μm) LD diameter (μm)
LD diameter (μm) LD diameter (μm)
LD
 si
ze
 d
ist
rib
ut
io
n 
(%
)
LD
 si
ze
 d
ist
rib
ut
io
n 
(%
)
LD
 si
ze
 d
ist
rib
ut
io
n 
(%
)
LD
 si
ze
 d
ist
rib
ut
io
n 
(%
)
LD
 si
ze
 d
ist
rib
ut
io
n 
(%
)
LD
 si
ze
 d
ist
rib
ut
io
n 
(%
)

% 
(
)
"
